Evgen Pharma

Evgen Pharma is a clinical stage drug development company focused on the treatment of cancer and neurological conditions. Evgen’s pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products.
Liverpool, GB
2 (est)
Evgen Pharma was founded in 2007 and is headquartered in Liverpool, GB

Evgen Pharma Locations

Liverpool, GB
London, GB

Evgen Pharma Metrics

Evgen Pharma Summary

Market capitalization

£15.7 M

Closing share price

Evgen Pharma's current market capitalization is £15.7 M.

Evgen Pharma Market Value History

Evgen Pharma Online Presence

Evgen Pharma News

Evgen Pharma Company Life

You may also be interested in